NVCR
HealthcareNovoCure Limited · Medical - Instruments & Supplies · $2B
What is NovoCure Limited?
NovoCure is an oncology company built around a novel approach to treating solid tumor cancers using electric fields rather than traditional drug therapies. Headquartered in Saint Helier, Jersey, it markets its devices across the US, Europe, Japan, and Greater China.
NovoCure develops, manufactures, and commercializes Tumor Treating Fields (TTFields) devices — wearable systems that deliver low-intensity electric fields to disrupt cancer cell division. Its two commercialized products target glioblastoma and malignant pleural mesothelioma. Beyond these approved indications, the company is running or has completed clinical trials across several additional cancer types, including non-small cell lung cancer, pancreatic cancer, ovarian cancer, and liver cancer, aiming to expand TTFields into a broader oncology platform.
NovoCure was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
- Optune — TTFields device approved for glioblastoma treatment
- Optune Lua — TTFields device for malignant pleural mesothelioma
- Clinical-stage TTFields programs across multiple solid tumor types
- Proprietary device manufacturing and patient support infrastructure
Is NVCR a Good Stock to Buy?
UQS Score rates NVCR as Below Average overall.
The strongest element in NovoCure's profile is its Risk pillar, which rates Good — reflecting a balance sheet and risk structure that holds up relatively well for a small-cap oncology company. Its Moat and Growth pillars both sit at Neutral, acknowledging the proprietary nature of TTFields technology while recognizing that commercial scale and competitive differentiation remain works in progress.
The Quality pillar rates Weak, pointing to underlying profitability challenges common to companies still investing heavily in clinical expansion. Valuation is rated Elevated, suggesting the market is pricing in considerable future success.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does NVCR pay dividends?
No — NovoCure Limited does not currently pay a dividend.
NovoCure does not currently pay a dividend. As a company still investing heavily in clinical trials and commercial expansion across multiple cancer indications, capital is directed toward research, device development, and market access rather than shareholder distributions. Income-focused investors should factor this into their assessment.
When does NVCR report earnings?
NovoCure reports earnings on a quarterly cadence, consistent with standard practice for US-listed equities.
Results in recent periods have reflected the tension between growing commercial revenues from approved indications and the ongoing cost of a broad clinical trial pipeline. Revenue trends and operating leverage remain key variables to watch as the company pursues label expansions.
For the most recent quarter's results and guidance, visit NovoCure's investor relations page directly.
NVCR Price History
-94.0% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in NovoCure Limited?
Based on NovoCure Limited's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
NVCR Long-term Outlook
NovoCure's fundamental outlook hinges on whether its TTFields platform can achieve meaningful penetration beyond glioblastoma. The Neutral Growth pillar reflects a business that has demonstrated some commercial traction but has not yet delivered the kind of accelerating revenue that would shift the growth profile materially. The Good Risk rating provides some reassurance about near-term financial stability, but the Elevated Valuation pillar signals that the current price embeds optimistic assumptions about pipeline success.
Growth drivers
- Potential label expansions into lung, pancreatic, and ovarian cancers
- Geographic expansion across Japan, Greater China, and EMEA markets
- Increasing physician and patient awareness of TTFields as a treatment modality
Key risks
- Clinical trial failures could undermine the platform's long-term growth thesis
- Elevated valuation leaves limited margin of safety if growth disappoints
- Reimbursement and payer coverage decisions remain a persistent commercial hurdle
NVCR vs Peers
NovoCure operates in the medical device and oncology space alongside other companies developing energy-based or device-driven therapeutic platforms.
AtriCure focuses on surgical ablation technologies for atrial fibrillation rather than oncology, representing a different application of energy-based therapy.
Kestra develops wearable cardioverter defibrillators, competing in the wearable medical device space but targeting cardiac rather than oncology indications.
Pulse Biosciences applies pulsed electric field technology to tissue treatment, making it a closer conceptual peer in energy-based cellular disruption.
Frequently Asked Questions
What does NovoCure do?
NovoCure develops and commercializes Tumor Treating Fields (TTFields) devices — wearable systems that use low-intensity electric fields to interfere with cancer cell division. Its two approved products target glioblastoma and malignant pleural mesothelioma, while a broad clinical pipeline explores additional solid tumor indications.
Does NVCR pay dividends?
No, NovoCure does not pay a dividend. The company reinvests available capital into clinical development and commercial expansion across multiple cancer types. Investors seeking income should be aware that no distribution is currently planned.
When does NVCR report earnings?
NovoCure follows a standard quarterly earnings cadence for US-listed companies. For the exact timing of upcoming reports and access to historical results, check NovoCure's official investor relations page.
Is NVCR a good stock to buy?
UQS Score rates NVCR as Below Average, reflecting a Weak Quality pillar and Elevated Valuation alongside a Neutral Moat and Growth profile. The Good Risk rating provides some stability context, but the overall composite suggests caution. The full pillar breakdown is available to Pro members.
Is NVCR overvalued?
The UQS Valuation pillar for NVCR is rated Elevated, indicating the stock is priced above what the current fundamental profile might typically support. This reflects market expectations for pipeline success that have not yet been confirmed by commercial results.
How does NVCR compare to its competitors?
NovoCure's TTFields platform is relatively unique among medical device peers. Competitors like Pulse Biosciences share some conceptual overlap in energy-based cell disruption, while AtriCure and Kestra operate in cardiac device markets. NovoCure's oncology focus and proprietary technology set it apart, though commercial scale remains a differentiating challenge.
What is NVCR's market cap bracket?
NovoCure is classified as a small-cap company. This places it in a segment where clinical and commercial execution risk tends to be higher, and where a single pipeline outcome can meaningfully shift the market's perception of long-term value.
Who founded NovoCure?
NovoCure was founded by Yoram Palti, an Israeli biophysicist who pioneered the concept of using alternating electric fields to disrupt cancer cell division. The company was incorporated in 2000 and has since built a commercial oncology platform around his foundational research.
Is NVCR a long-term quality indicator?
From a UQS perspective, NVCR's long-term quality profile is mixed. The Weak Quality pillar reflects current profitability pressures, while the Neutral Moat suggests the TTFields technology offers some differentiation without yet constituting a dominant competitive position. Long-term quality will depend heavily on pipeline outcomes.
What is the main competitive advantage of NovoCure?
NovoCure's primary advantage is its proprietary TTFields technology, which has no direct equivalent among approved cancer therapies. The platform's ability to be used alongside standard treatments without the toxicity profile of chemotherapy is a meaningful clinical differentiator — though building durable commercial moat around it remains an ongoing effort.
What sector does NVCR belong to?
NovoCure operates in the Healthcare sector, specifically within oncology medical devices. It sits at the intersection of biotech-style clinical risk and medical device commercialization, which shapes both its growth potential and its risk profile as assessed by the UQS framework.
Is NVCR a growth stock or value stock?
Based on UQS pillar labels, NVCR leans toward a growth-oriented profile — its Valuation is Elevated and its Growth pillar is Neutral, suggesting the market is paying a premium for future potential rather than current earnings. It does not exhibit the characteristics typically associated with value investing.
Unlock Full NVCR Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access detailed financial metrics and trend data
- ✓Compare NVCR against sector peers side by side
- ✓Track Quality, Moat, Growth, Risk, and Valuation over time
- ✓Get the full analyst view available only to Pro members
Pro Analysis
NVCR — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 16, 2026 | 35.0 | 16.7 | 42.0 | 45.0 | 75.7 | 0.0 | +0.3 |
| May 4, 2026 | 34.7 | 16.7 | 42.0 | 45.0 | 73.8 | 0.0 | +0.7 |
| Apr 2, 2026 | 34.0 | 16.7 | 42.0 | 41.6 | 73.8 | 0.0 | — |
NVCR — Pillar Breakdown
Quality
— 16.7/100 (25%)NovoCure Limited currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 45.0/100 (20%)NovoCure Limited shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 75.7/100 (15%)NovoCure Limited carries minimal financial risk with conservative leverage and strong solvency.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)NovoCure Limited appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 42/100 (25%)NovoCure Limited possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for NVCR.
Score Composition
Financial Data
More Stock Analysis
How is the NVCR UQS Score Calculated?
The UQS (Unified Quality Score) for NovoCure Limited is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses NovoCure Limited's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether NovoCure Limited is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.